The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is curr...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-12-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/the-impact-of-ribavirin-on-real-world-adherence-rates-in-hepatitis-c-p-peer-reviewed-article-CEOR |